Lombard Medical Technologies has defaulted on a loan and said it doesn't have enough cash to survive past the first half of this year. Here's a look at how things went from bad to worse for Lombard.
The transcatheter aortic valve replacement market has already seen rapid growth. But the market leaders say they've only scratched the surface in terms of the growth opportunities in the space.
Angiodynamics updated investors on its lawsuit against C.R. Bard, an effort the company launched last year to level the playing field in the PICC market.
FDA gave MR-conditional labeling to two of Abbott's cardiac rhythm management (CRM) devices, a move that further boosts the company's ability to compete with its peers in the space.
China has cleared Becton, Dickinson and Company's pending $24 billion acquisition of C.R. Bard, and the deal is expected to close Dec. 29.
Cordis has distribution rights to sell Medinol's newly approved EluNIR drug-eluting stent in the United States.
Boston Scientific pushed back its timelines for re-introducing the Lotus Edge aortic valve system in Europe and the filing of a final pre-market approval module with FDA.
Researchers and device developers have been taking aim at many of the shortcomings associated with current pacemakers, and these breakthroughs could usher in a new generation of pacemaker technologies.
Medtronic's new pacemaker technology includes access restrictions to protect the device functionality and patient data.
LivaNova plans to divest its cardiac rhythm management business to MicroPort for $190 million in cash.
A Chicago startup that seeks to 3-D print human hearts for transplantation has added to its scientific advisory board of heavy hitters. But just how close is the company to producing its first viable heart?
Everything you need to know about transcatheter mitral valve therapies, the latest in drug-eluting stents, and other key findings presented at this year's Transcatheter Cardiovascular Therapeutics meeting.
After a six-year hiatus from the coronary stent business, Cordis just inked an exclusive distribution deal for two heart stents.
A recent scientific statement by the American Heart Association shines a spotlight on cardiovascular genomic testing and gives a nod to two such technologies that are currently on the market.